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Abstract
Background: Diarrhea is a serious concern worldwide, especially in developing countries. Rotavirus is implicated in
approximately 400,000 infant deaths annually. It is highly contagious elevating the risk of outbreaks especially in
enclosed settings such as daycare centers, hospitals, and boarding schools. Reliable testing methods are critical for
early detection of infections, better clinical management, pathogen surveillance and evaluation of interventions
such as vaccines. Enzyme immunoassays have proved to be reliable and practical in most settings; however, newer
multiplex reverse transcription polymerase assays have been introduced in the Kenya market but have not been
evaluated locally.
Methods: Stool samples collected from an ongoing Surveillance of Enteric Pathogens Causing diarrheal illness in
Kenya (EPS) study were used to compare an established enzyme immunoassay, Premier™ Rotaclone® (Meridian
Bioscience, Cincinnati, Ohio, U.S.A.), that can only detect group A rotavirus against a novel multiplex reverse
transcription polymerase chain reaction kit, Seeplex® Diarrhea-V ACE Detection (Seegene, Seoul, Republic of Korea),
that can detect rotavirus, astrovirus, adenovirus, and norovirus genogroups I and II. Detection frequency, sensitivity,
specificity, turnaround time, and cost were compared to determine the suitability of each assay for clinical work in
austere settings versus public health work in well-funded institutes in Kenya.
Results: The Premier™ Rotaclone® kit had a detection frequency of 11.2%, sensitivity of 77.8%, specificity of 100%,
turnaround time of 93min and an average cost per sample of 13.33 United States dollars (USD). The Seeplex® Diarrhea-
V ACE Detection kit had a detection frequency of 16.0%, sensitivity of 100%, specificity of 98.1%, turnaround time of
359min and an average cost per samples 32.74 United States dollars respectively. The detection frequency sensitivity
and specificity of the Seeplex® Diarrhea-V ACE Detection kit mentioned above are for rotavirus only.
Conclusions: The higher sensitivity and multiplex nature of the Seeplex® Diarrhea-V ACE Detection kit make it suitable
for surveillance of enteric viruses circulating in Kenya. However, its higher cost, longer turnaround time and complexity
favor well-resourced clinical labs and research applications. The Premier™ Rotaclone®, on the other hand, had a higher
specificity, shorter turnaround time, and lower cost making it more attractive for clinical work in low complexity labs in
austere regions of the country. It is important to continuously evaluate assay platforms’ performance, operational cost,
turnaround time, and usability in different settings so as to ensure quality results that are useful to the patients and
public health practitioners.
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Background
Diarrheal disease is a leading cause of mortality and
morbidity worldwide that places a considerable financial
burden on health care systems and patients [1]. Though
short-lived, the associated morbidity is significant [2], es-
pecially among children younger than the age of five
where 1 in 9 child deaths worldwide is caused by diar-
rheal disease. This translates to 17% of all deaths in this
age group which is more than deaths associated with ac-
quired immune deficiency syndrome (AIDS), malaria
and measles combined. Approximately two thirds of
these deaths occur in sub-Saharan Africa and South Asia
[3, 4]. Previous studies have indicated that the risk of in-
fections and outbreaks is elevated among people work-
ing or living in enclosed communities such as nursing
homes, hospitals, prisons, daycare centers, boarding
schools, and military camps [5].
Among the enteric viruses, rotavirus stands out as the
leading cause of infectious diarrhea in infants and chil-
dren worldwide [6]. Each year, rotavirus causes approxi-
mately 25 million clinic visits, 2 million hospitalizations,
and between 352,000 to 592,000 deaths (median: 440,
000 deaths) in children < 5 years of age [7]. The virus is
very stable in the environment and can remain infectious
for weeks within raw food, treated and untreated water,
which all represent possible sources of rotavirus gastro-
enteritis outbreaks [8].
Rotavirus disease imposes a heavy economic burden
due to factors such as medical consultation and treat-
ment as well as loss of time at work. Although rotavirus
is generally the most common enteric pathogen in chil-
dren worldwide, its role (and that of other enteric vi-
ruses) in many parts of Kenya is less understood due to
limited resources and laboratory challenges in remote
areas of the country. Rotavirus diarrhea is estimated to
cause about 19–27% of all diarrhea hospitalizations of
children < 5 years in Kenya where it is still the most
common cause of severe gastroenteritis in children des-
pite ongoing vaccination [9, 10]. It was noted in Peru
that the rate of rotavirus infection and its associated dis-
ease burden is higher in the second year of life despite
vaccine compliance. This observation indicates that pro-
tection by the vaccine may not be sustained beyond the
first year of life in some populations [10–12].
Rotavirus is also known to cause diarrhea in older chil-
dren and adults with severe illness occurring in im-
munocompromised hosts. Healthy adults and children
who are carriers may not feel the disease burden, but
they act as viable reservoirs and potential sources of out-
breaks. Studies have shown that there is a high likeli-
hood of back and forth infections between children and
adults [13]. For these reasons, adults and healthy chil-
dren (controls) who are part of EPS study were included
in this study.
Laboratory diagnosis of rotavirus infection is usually
performed using various techniques both conventional
and molecular. Enzyme immunoassays (EIAs) are used
as the standard test for rotavirus infection in many parts
of the world [14]. Several polymerase chain reaction
(PCR)-based protocols for the detection of human en-
teric viruses with higher sensitivities have been pub-
lished, but only a few of them allow for simultaneous
detection of the major enteric viruses in one assay. This
is a necessary capability in order to understand the dis-
ease burden associated with viral gastroenteritis caused
by multiple viruses circulating in Kenya [15, 16]. Diag-
nostic capabilities to detect a broad spectrum of diar-
rheal pathogens is lacking in many parts of the Kenya
with many health care providers relying on empirical
diagnosis without laboratory confirmation, a practice
that can result in misdiagnosis and prescription of in-
appropriate treatment [4, 17, 18]. Clinical testing for
rotavirus in the country is mostly done only in well-
funded hospitals in urban areas, and is rarely done in re-
mote regions where laboratories have insufficient re-
sources. In places where testing is done, EIA and
Reverse Transcription PCR (RT-PCR) are the most com-
monly applied techniques for rotavirus testing in Kenya
[12, 19, 20].
A review of the epidemiology of human rotavirus asso-
ciated with diarrhea in Kenyan children between 1975 to
2005 reported EIAs as the most commonly used testing
platform followed by RT-PCR, polyacrylamide gel elec-
trophoresis (PAGE), culture and fluorescence focus
neutralization (FFN) respectively [21]. EIA was the
screening platform of choice for the Rotavirus Vaccine
Impact Evaluation in Kenya (RIPEK) study that was re-
cently conducted by CDC Kenya, KEMRI-Welcome
Trust and KEMRI-Walter Reed Program (currently
known as USAMRD-A) [22]. It was also the rotavirus-
testing platform of choice for various surveillance stud-
ies including the African Rotavirus Surveillance Network
among others [12, 23]. EIAs have proven to be reliable
in Kenya making them good tool to compare newer
multiplex platforms that are emerging in the country.
This study compared a multiplex RT-PCR assay, See-
plex® Diarrhea-V ACE Detection (Seegene, Seoul, Repub-
lic of Korea), capable of detecting five enteric viruses
(rotavirus, adenovirus, astrovirus, norovirus GI and GII)
[24] to the established singleplex EIA, Premier™ Rota-
clone® (Meridian Bioscience, Cincinnati, Ohio), that has
been previously used for several rotavirus surveillance
studies in well-funded research institutions in Kenya
[25]. Even though Premier™ Rotaclone® has been used as
a reference assay for an evaluation study done in Kenya
[26], there is paucity of information on its evaluation
and performance in the country. A study done in Niger
in 2017 reported the Premier™ Rotaclone® to have a
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sensitivity of 80.7% (95% confidence interval 72.4–
87.3%) and specificity of 100% (95% confidence interval
97.2–100%) [27]. Similarly there is paucity of informa-
tion regarding evaluation and performance of Seeplex®
Diarrhea-V ACE Detection kit in Kenya, an evaluation
and verification study done in Canada reposted specifi-
city and sensitivity of 100% for rotavirus [24]. This study
sought to determine the suitability of the newer multi-
plex Seeplex® Diarrhea-V ACE Detection kit over the
established Premier™ Rotaclone® kit by evaluating turn-
around time (TAT), sensitivity, specificity and average
cost. We hypothesized that there is no difference in the
performance and cost of the 2 assays.
Real-time PCR (qRT-PCR) platforms detect products
on-site by measuring fluorescence on each well making
it more sensitive than the ethidium bromide-based de-
tection method used by many conventional RT-PCRs
kits including the Seeplex® Diarrhea-V ACE Detection
kit. Unlike conventional RT-PCR that detects products
at the plateau stage of the reaction, qRT-PCR detects
products at the exponential stage thus it is less vulner-
able to product degradation at later stages [28]. qRT-
PCR also excludes ambiguity of positive/negative inter-
pretation, which is a common issue with conventional
RT-PCR products as faint bands may be difficult to in-
terpret and can easily introduce bias [28, 29]. Because of
its higher sensitivity and superior performance, qRT-
PCR was used as the reference assay in this study.
This study seeks to address the paucity of performance
information regarding enteric viruses’ detection assays
using samples from Kenya and other developing coun-
tries.. Findings from this study will be useful in elucidat-
ing the best testing platforms to employ for the
detection of rotavirus in routine clinical and research
settings in Kenya and other developing countries. This
will help policy makers and other stakeholders in the
health sector make more informed decisions regarding




Stool samples tested in this study were obtained from
participants enrolled in the ongoing EPS study in Kenya.
Based on the EPS study protocol, we enrolled acute, un-
complicated diarrhea cases and asymptomatic age-
matched controls of all ages in several outpatient depart-
ments of various Ministry of Health (MoH) facilities in
Kenya. A total of 125 stool samples collected from sub-
jects enrolled into the EPS study from April 2013 to
January 2018 used in this study. The samples were
stored at − 80 °C in monitored freezers prior to testing;
no preservatives were added to the samples.
Inclusion criteria
Patients presenting with acute diarrhea defined as having
3 or more loose/watery stools within a 24-h period, last-
ing less than 14 days in duration and without antibiotic
use were enrolled in the study as cases at the outpatient
clinic of each sentinel site. Patients visiting outpatient
departments of the same hospitals, whom had not had
diarrhea within the previous 2 weeks, were enrolled as
age-matched controls for the cases.
Exclusion criteria
Individuals with chronic diarrhea (lasting more than 2
weeks), those who had taken antibiotics, those admitted
into inpatient departments and those unwilling to pro-
vide informed consent were excluded from the study.
Study location
This study was conducted at the United States Army
Medical Research Directorate-Africa (USAMRD-A)
Microbiology Hub Kericho (MHK) Kenya. The MHK
conducts research in collaboration with the Kenya Med-
ical Research Institute (KEMRI) and other institutions
on the etiology of diarrheal disease in Kenya and re-
ceives samples from various government and military
hospitals/clinics within Kenya.
Scientific and ethical review
The Surveillance of Enteric Pathogens Causing diarrheal
illness in Kenya (WRAIR # 1549/ KEMRI SCC# 1549)
(EPS) study was approved by the KEMRI and the Walter
Reed Army Institute of Research (WRAIR) institutional
review boards (IRBs). This comparison of diagnostic
methods study was conducted as a sub-study of the EPS
study and was approved by the KEMRI and WRAIR
IRBs and designated as WRAIR #2443 and KEMRI/
SERU/CCR/0052/3384.
Laboratory analysis of stool samples
Rotavirus testing by the EIA
The Premier™ Rotaclone® kit (Meridian Bioscience, Cin-
cinnati, Ohio, U.S.A) was used according to the manu-
facturer’s instructions. Briefly, a 1:10 dilution of stool
sample was prepared by adding 1 ml/1 g of stool and 10
ml of sample diluents to a well. The diluted sample was
mixed with the enzyme conjugate, incubated at room
temperature for 60 min, carefully poured off and wells
washed five times with sterile deionized water. Enzyme
substrates were added to each well and incubated at
room temperature for 10 min. A total of 100 μl of stop
solution was added followed by visual determination of
reactivity relative to positive and negative controls pro-
vided by the kit manufacturer.
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Rotavirus detection by RT-PCR
The ZR Soil/Fecal RNA Microprep™ kit (Zymo Research,
California, U.S.A) was used for RNA extraction accord-
ing to the manufacturer’s instructions. Quality and quan-
tity of the extracted RNA was measured at 260 and 280
nm using a NanoDrop™ 2000 Spectrophotometer, a con-
centration > 1.8 was considered good enough for subse-
quent steps. Reverse transcription was done using the
RevertAid First Strand cDNA Synthesis kit (Thermo Sci-
entific, Vilnius, Lithuania) according to the manufac-
turer’s instructions. Synthesized cDNA was amplified
using the Seeplex® Diarrhea-V ACE Detection kit (See-
gene, Seoul, Republic of Korea) according to the manu-
facturer’s instructions. Amplicons were visualized using
Ultraviolet irradiation after electrophoresis on a 3% agar-
ose gel. Positive, negative and internal controls provided
by the kit manufacturer were included in every run.
Resolution of discordant samples by real time RT-PCR (qRT-
PCR)
qRT-PCR platform has been documented to have better
performance than EIAs and conventional RT-PCR due
to better detection of PCR products and reduced ambi-
guity in negative and positive samples [28, 29]. For these
reason a qRT-PCR platform (Rotavirus/Norovirus/Astro-
virus Real-Time kit by Sacace™ Biotechnologies, Como,
Italy) was used as the reference assay in this study. The
kit was used according to the manufacturer’s instruc-
tions. PCR cycling parameters were as follows: 2 holding
stages at 50°C and 90°C for 30 min and 15 min respect-
ively followed by 45 cycles at 95°C for 10 s, 60°C for 25 s
and 72°C for 10 s. A Ct value lower than 33 was consid-
ered positive as instructed by the kit manufacturer.
Statistical analysis
Sensitivity and specificity
Sensitivity and specificity were calculated as described
by R. Parikh [30]. Even though Premier™ Rotaclone® is
more established and often used as a reference assay, it
has displayed varying sensitivities and specificities in dif-
ferent settings. Its sensitivity and specificity are 100 and
92% respectively according to the manufacturer while
studies done in different settings have reported sensitiv-
ities of 76.8 to 80.7% in U.S.A and Niger respectively.
Both studies reported 100% specificity [27, 31]. For this
reason we sought to determine its sensitivity alongside
that of the Seeplex® Diarrhea-V ACE Detection kit in the
Kenya setting. A qRT-PCR assay was used as a reference
assay.
Turnaround time (TAT)
In this study, TAT was defined as the time taken from
the beginning of sample processing to obtaining and val-
idating the results [32]. TATs per run for both methods
were recorded and used to find the mean TAT for each
assay and the difference in means using the Student’s t-
test.
Determination of average cost
Information on input for materials and unit costs associ-
ated with rotavirus testing by each assay such as cost of
reagents and disposable supplies including test kits were
considered [33]. The average cost per test by each assay
was determined by dividing the total cost of each assay
by the total number of samples tested. Due to high level
of variability in prices of laboratory equipment depend-
ing on manufacturers and capabilities, those that are re-
quired by the assays evaluated in this study were only
listed for readers’ consideration.
Results
Sensitivity, specificity, predictive values and diagnostic
accuracy
A total of 125 stool samples were tested in this study.
Premier™ Rotaclone® kit detected rotavirus in 11.2% (14/
125) while Seeplex® Diarrhea-V ACE Detection kit de-
tected rotavirus in 16.0% (20/125). Seeplex® Diarrhea-V
ACE Detection kit detected rotavirus in 25.4%, (16/63)
of cases and 6.5% (4/62) of the controls. On the other
hand, Premier™ Rotaclone® kit detected rotavirus in
22.2% (14/63) of cases and in none of the controls as
shown in Tables 1 and 2. Discordant samples noted were
from 4 controls and 2 cases, resolution by qRT-PCR re-
vealed that the 2 cases and 2 of the controls were true
positives while the other 2 controls turned out to be
false positives. No cross-reactivity was observed in any
of the assays. Sensitivity and specificity were calculated
after resolution of discordant samples by qRT-PCR.
The sensitivity and specificity of the Seeplex®
Diarrhea-V ACE detection were 100% (95% confidence
interval 81.5 to 100.00%) and 98.1% (95% confidence
interval 93.41 to 99.77%) respectively, and those of the
Table 1 Distribution of Rotavirus among study participants
Subjects ≤5 yrs. of age (n = 64) Subjects > 5 yrs. of age (n = 61) Total
Males (n = 33) Females (n = 31) Males (n = 27) Females (n = 34)
Cases 7 6 0 0 13
Controls 2 0 2 1 5
Total 9 6 2 1 18
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Premier™ Rotaclone® were 77.8% (95% confidence inter-
val 52.36 to 93.59%), and 100% (95% confidence interval
96.61 to 100.00%) respectively as shown in Table 3
Turnaround time (TAT)
The mean TAT per run of 10 samples was 93min and
359 min for the Premier™ Rotaclone® and the Seeplex®
Diarrhea-V ACE Detection respectively (Table 3). The
difference in mean TATs was 266 min (95% confidence
interval from 262 to 270 min). The Seeplex® Diarrhea-V
ACE Detection kit takes more than threefold the amount
of time it takes to run the Premier™ Rotaclone®.
Cost
The average cost of kits/reagents used for testing one
sample was 13.33USD and 32.94USD for the Premier™
Rotaclone® and the Seeplex® Diarrhea-V ACE Detection
assay respectively (Table 4). The Premier™ Rotaclone®
only required one kit, a pipette, pipette tips, and sterile
tubes while the RT-PCR assay required 2 additional kits
(an RNA extraction and a reverse transcription kit), as
well as Thermo Scientific™ NanoDrop™ 2000 Specrtophot-
ometer~ 9700USD, a thermocycler (Applied Biosystems
Veriti 96 well thermocycler ~7000USD), high-speed cen-
trifuge (Eppendorf Microcentrifuge ~3000USD), an elec-
trophoresis power supplier (Thermo Scientific Owl EC-
200 XL Hi Current Power supply~ 2000USD), an electro-
phoresis chamber (Thermo Scientific Owl A1 Large Gel
System~650USD), and a gel imaging system (Alpha Inno-
tech AlphaImager HP~ 2500 USD). Unlike consumable
reagents and test kits that are bought frequently and have
predictable prices, laboratory equipment are not bought
frequently and vary greatly in prices depending on their
capabilities and vendors. For these reasons, cost of
equipment used in this study are only listed for readers’
consideration but not included alongside consumable re-
agents and kits in calculation of the average cost per sam-
ple represented in Table 4.
Additional findings
Due to the multiplex nature of the Seeplex® Diarrhea-V
ACE Detection kit, we detected a variety of enteric vi-
ruses including a 1 subject who had a rotavirus/noro-
virus co-infection (Table 5).
Discussion
In this study, the Seeplex® Diarrhea-V ACE Detection kit
showed a higher detection frequency and was more sen-
sitive than the Premier™ Rotaclone®. The two kits had
detection frequencies of 25.4 and 22.2% respectively
among cases, all of these were children below 5 years of
age. These resulted closely reflects prevalence of 14.5 to
31% that were reported in recent epidemiologic studies
done in Kenya among children below 5 years of age hos-
pitalized with diarrhea [10, 12]. The higher detection fre-
quency and sensitivity of the RT-PCR assay could be
attributed to its lower detection limit documented by
the manufacturer (100 copies/3 μl DNA) that enables it
to detect trace amounts of viral nucleic acids excreted in
stool samples. The observation that rotavirus was de-
tected in asymptomatic controls by RT-PCR could be at-
tributed to the fact that the virus’ nucleic acid is likely to
remain detectable for a longer period after the subjects
has recovered. In contrast, the EIA targets antigens that
are rarely detected more than 1 week after onset of ill-
ness [34]. Asymptomatic controls have also tested posi-
tive by RT-PCR in other studies including one recently
done in Niger [27]. The higher sensitivity (100%) of the
Seeplex® Diarrhea-V ACE Detection kit was observed in
an evaluation and verification study done in Canada
[24]. The higher specificity (100%) exhibited by Premier™
Rotaclone® in this study is also in agreement with previ-
ous studies comparing EIA and RT-PCR detection assays
U.S.A [31].
The mean TAT per run of 10 samples for Seeplex®
Diarrhea-V ACE Detection kit was more than three-fold
longer than the TAT for Premier™ Rotaclone®. This was
due to several steps involved in the RT-PCR assay that
Table 2 Rotavirus detection frequency and descriptive metrics






Cases n = 63 16/63 (25.4%) 14/63 (22.22%)
Controls n = 62 4/62 (6.4%) 0/62 (0)
Total = 125 20/125 (16.0%) 14/125 (11.2%)
Table 3 Comparison of the sensitivity and specificity of the Seeplex® Diarrhea-V ACE Detection and Premier™ Rotaclone® assays
Seeplex® Diarrhea-V ACE Detection (n = 125) Premier™ Rotaclone® (n = 125)
True positives 18 14
False positives 2 0
True negatives 105 107
False negatives 0 4
Sensitivity 100% (95% CI: 81.5 to100%) 77.8% (95% CI: 52.36 to 93.59%)
Specificity 98.1% (95% CI: 93.41 to99.77%) 100% (95% CI: 96.61 to 100.00%)
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include RNA extraction, reverse transcription, and amp-
lification. This difference in mean TATs is an important
consideration in clinical settings where shorter TATs are
of great importance for patient treatment and care [18].
It is important to note that the Seeplex® Diarrhea-V ACE
Detection kit is able to detect five different diarrhea
causing viruses (rotavirus, adenovirus, astrovirus, noro-
virus GI and GII) within the time noted whereas the
Premier™ Rotaclone® can only detected rotavirus. See-
plex® Diarrhea-V ACE Detection kit was able to detect
norovirus GII in 12 samples (8 from children below 5
years and 4 from individual above 5 years), adenovirus in
6 samples (5 from children under 5 years and 1 from a 6
years old child), 1 astrovirus from a 5 years old child and
one rotavirus/norovirus GII co infection from a 1 year
and 4months old child. This gives a hint of the heavy
disease burden imposed especially on children below 5
years old by enteric viruses circulating in Kenya. As ob-
served by Goldenberg et al. 2015, the ability to detect
multiple pathogens is an important consideration to
make when identifying platforms to use for future clin-
ical as well as outbreak investigations and surveillance
work [35].
The average cost of testing one sample by Seeplex®
Diarrhea-V ACE Detection was more than 2-fold higher
than that of testing by the Premier™ Rotaclone®. The
higher cost can be attributed to the fact that the RT-
PCR assay required an RNA extraction, reverse tran-
scription as well as amplification kits whereas the Prem-
ier™ Rotaclone® procedure only required one kit.
Seeplex® Diarrhea-V ACE Detection also utilized more
laboratory equipment: a spectrophotometer, thermocy-
cler, a high-speed centrifuge, an electrophoresis power
supplier, an electrophoresis chamber, and a gel imaging
system making its operational cost much higher than
the Premier™ Rotaclone®. The Premier™ Rotaclone® re-
quired fewer supplies due to fewer steps involved in its
procedure. The RT-PCR platform had longer steps with
both RNA extraction and agarose gel electrophoresis
that required more supplies. This made the Seeplex®
Diarrhea-V ACE Detection assay more labor intensive
and time consuming than the EIA platform [36].
Accurate diagnosis and surveillance of rotavirus and
other enteric viruses causing diarrhea in Kenya is critical
for the rapid identification of infected patients who are
potential sources of infection to others. Having this cap-
ability at the point-of-care or as close as possible would
enhance patient management, reduce the spread of en-
teric pathogens, and improve the management of disease
burden, especially among children [37]. Evaluation stud-
ies like this will ensure quality and improvement of en-
teric viruses’ testing assays, implementation of better
testing platform, improved knowledge on disease dy-
namics and better patient care. These outcomes will
have a beneficial effect especially on the health of chil-
dren in Kenya and other developing countries that bear
the biggest disease burden associated with enteric vi-
ruses. This will lead to better growth, development and
general well being of such children.
Conclusion
In this study, the Seeplex® Diarrhea-V ACE Detection kit
(Seegene, Seoul, Republic of Korea), a RT-PCR, showed
a higher detection frequency and sensitivity compared to
the established EIA, Premier™ Rotaclone® kit(Meridian
Bioscience, INC, Cincinnati Ohio, U.S.A). However, the
Premier™ Rotaclone® kit had a higher specificity, lower
average cost, and shorter TAT.
With a higher detection frequency, sensitivity, and
ability to detect 5 viruses, the Seeplex® Diarrhea-V ACE
Detection kit is an ideal tool for outbreak investigations
and surveillance of enteric viruses causing diarrhea in
Kenya. Its higher cost, complexity, and longer TAT make
it unsuitable for routine clinical testing especially in aus-
tere setups within Kenya and other developing nations.











Table 5 Enteric viruses detected by the Seeplex® Diarrhea-V ACE Detection Assay
Subjects ≤5 yrs. of age (n = 64) Subjects > 5 yrs. of age (n = 61) Total
Males Females Males Females
Rotavirus 9a 6 2 3 20
Adenovirus 3 2 0 1 6
Astrovirus 1 0 0 0 1
NoVGI 0 0 0 0 0
NoVGI1 3a 5 2 2 12
Total 16 23 4 6 39
a1 case of rotavirus-norovirus GII co infection
Philip et al. Tropical Diseases, Travel Medicine and Vaccines            (2019) 5:12 Page 6 of 9
However, if validated and approved by the relevant au-
thorities in Kenya, it can be a useful tool in well-funded
clinical laboratories within the country. This platform
can be easily implemented in well-funded research insti-
tutions in Kenya and can play an important role in eluci-
dating the incidences, prevalence, distribution, and
disease burden associated with enteric viruses circulating
in the country. The longer TAT and higher cost of the
Seeplex® Diarrhea-V ACE assay may be justifiable by the
number of viruses it can detect in each run.
The Premier™ Rotaclone® is suitable for routine clinical
testing of rotavirus especially in austere settings in
Kenya. It has a shorter turnaround time, is 100% spe-
cific, cheaper and can be easily implemented even in re-
mote clinics that have limited resources and financial
constraints that inhibit their ability to implement com-
plex platforms like RT-PCR.
Further evaluation and validation of newer multiplex
assays that can detect several enteric pathogens includ-
ing parasites and bacteria circulating in Kenya should be
encouraged, as this will elucidate their applicability and
make scientists and policy makers aware of the most
suitable platforms to implement in routine clinical and
research work in Kenya. The additional data that multi-
plex assays are able to provide can enhance surveillance
of etiological agents causing diarrheal illness and en-
hance public health measures and policy decisions on
diarrheal diseases. Other than rotavirus, there is very
limited information on the prevalence and trends of
other enteric viruses circulating in Kenya. As rotavirus
studies continue, more effort should be put on studying
the other enteric viruses as well. This should be done by
the most suitable testing platforms that can be imple-
mented efficiently to generate the most accurate data
possible.
Limitations of the study
Limitations of this study include the fact that we did not
look at severity of illness and focused only on 5 enteric
viruses thus we cannot provide information on other
pathogens including bacteria and parasites that are the
other likely causes diarrhea in the cases that were nega-
tive for the enteric viruses tested in this study.
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